Sirona Biochem Announces Cfda Approval Of Sglt2 Inhibitor For Phase I Clinical Trial | Latest News RSS feed

Sirona Biochem Announces Cfda Approval Of Sglt2 Inhibitor For Phase I Clinical Trial - Latest News


Sirona Biochem Announces Results of AGM & CEO Update

Kevin will be part of the Sirona Biochem team attending the JPMorgan parallel conference in San Francisco, California in early January. SGLT2 Inhibitor ... months to approve the filing. Approval for t... read more

China Biotech In Review: Eli Lilly Joins The Big Pharmas Accused Of Bribing In China

The proceeds will be used to fund the US-China development of MRX-I, which has completed a Phase I clinical trial ... treatment from Sirona Biochem of Canada. The molecule is a member of a new class o... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us